ArticleThe Journal of general virology2026
Immunogenicity of SARS-CoV-2 vaccine prototype based on virus-like particles of hepatitis B core antigen from genotype G and interleukin 12 expressing Semliki Forest virus as a genetic adjuvant.
Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Virus-like particles (VLPs) based on hepatitis B core antigen (HBc) represent an immunogenic and modular platform for epitope presentation. In this study, the VLPs formed by the modified recombinant hepatitis B core antigen from genotype G (HBc/G) were used as carriers for the presentation of a receptor-binding motif (RBM) of the Delta variant of Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). The RBM was inserted at the C-terminus of the modified HBc/G extended by the addition of a second, specifically modified C-terminal domain of HBc/G. All arginine residues in the extra domain were replaced with glycine, resulting in a 'two-tailed' HBc/G-Gly vector. The resulting HBc/G-Gly-RBM construct successfully formed regular VLPs in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.